康泰生物：获得《药物临床试验批准通知书》

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has received approval for clinical trials of its trivalent influenza virus split vaccine, indicating progress in its vaccine development efforts [2]. Group 1 - The trivalent influenza virus split vaccine (MDCK cell) was developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [2] - The approval was granted by the National Medical Products Administration, confirming that the vaccine meets the necessary requirements for drug registration [2]. - The clinical trial approval is in accordance with the Pharmaceutical Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China [2].